CA3217136A1 - Methods and compositions for treatment of diabetic retinopathy and related conditions - Google Patents

Methods and compositions for treatment of diabetic retinopathy and related conditions Download PDF

Info

Publication number
CA3217136A1
CA3217136A1 CA3217136A CA3217136A CA3217136A1 CA 3217136 A1 CA3217136 A1 CA 3217136A1 CA 3217136 A CA3217136 A CA 3217136A CA 3217136 A CA3217136 A CA 3217136A CA 3217136 A1 CA3217136 A1 CA 3217136A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
patient
orally administered
certain embodiments
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217136A
Other languages
English (en)
French (fr)
Inventor
Mina SOOCH
Konstantinos Charizanis
Mark R. Kelley
Richard Adam Messmann
Mitchell George BRIGELL
Ronil Ajaykumar PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Ocuphire Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocuphire Pharma Inc filed Critical Ocuphire Pharma Inc
Publication of CA3217136A1 publication Critical patent/CA3217136A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3217136A 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions Pending CA3217136A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182037P 2021-04-30 2021-04-30
US63/182,037 2021-04-30
PCT/US2022/027062 WO2022232597A1 (en) 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions

Publications (1)

Publication Number Publication Date
CA3217136A1 true CA3217136A1 (en) 2022-11-03

Family

ID=83848745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217136A Pending CA3217136A1 (en) 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions

Country Status (11)

Country Link
US (1) US20240216315A1 (enExample)
EP (1) EP4329741A4 (enExample)
JP (1) JP2024516003A (enExample)
KR (1) KR20240049212A (enExample)
CN (1) CN117500492A (enExample)
AU (1) AU2022264037A1 (enExample)
BR (1) BR112023022561A2 (enExample)
CA (1) CA3217136A1 (enExample)
IL (1) IL308083A (enExample)
MX (1) MX2023012793A (enExample)
WO (1) WO2022232597A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4587003A2 (en) 2022-09-14 2025-07-23 Opus Genetics, Inc. Salts and esters of apx3330 and therapeutic uses thereof
WO2024158972A1 (en) * 2023-01-25 2024-08-02 Ocuphire Pharma, Inc. Methods and compositions for preventing the progression of diabetic retinopathy and related conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008304619C1 (en) * 2007-09-26 2020-06-04 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
AU2019218797B2 (en) * 2018-02-08 2023-09-21 Indiana University Research And Technology Corporation Targeting ocular diseases with novel APE1/Ref-1 inhibitors

Also Published As

Publication number Publication date
BR112023022561A2 (pt) 2024-01-02
MX2023012793A (es) 2024-01-11
US20240216315A1 (en) 2024-07-04
JP2024516003A (ja) 2024-04-11
CN117500492A (zh) 2024-02-02
IL308083A (en) 2023-12-01
AU2022264037A1 (en) 2023-11-16
EP4329741A4 (en) 2025-01-08
EP4329741A1 (en) 2024-03-06
WO2022232597A1 (en) 2022-11-03
KR20240049212A (ko) 2024-04-16

Similar Documents

Publication Publication Date Title
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
JP5341933B2 (ja) 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP2524693B1 (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
US11723890B2 (en) Methods of treatment using an mTORC1 modulator
US12102640B2 (en) Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
CN119745879A (zh) 包含阿西替尼的组合物和治疗眼部疾病的方法
US20240216315A1 (en) Methods and compositions for treatment of diabetic retinopathy and related conditions
AU2024204716A1 (en) Treatment of alopecia areata
US20240148709A1 (en) Methods of treating eye pain and eye disorders
US20260108483A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
US20240252497A1 (en) Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
JP2024518787A (ja) 全身型重症筋無力症の処置のための補体因子ｄ阻害剤の使用
WO2025072687A1 (en) Methods and compositions for treatment of geographic atrophy
HK40101374A (en) Compositions and methods for treating pterygium
HK1253895B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425